Letter to the Editor
Why Should We Avoid the Use of Rosiglitazone?
Abstract
To the Editor:
The recent release of data regarding the cardiovascular (CV) safety of rosiglitazone (Avandia) raised major public concern. The author presents herein an updated summary of CV safety data of rosiglitazone and provides a rationale for avoiding its use outside the setting of clinical trials.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.